BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase ( RdRp ) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC 50 for SARS-CoV-2 and HCoV-229E are 0.62 µM and 0.14 µM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir.